NorthCrest Asset Manangement’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$398K Buy
2,018
+300
+17% +$51.6K 0.01% 626
2026
Q1
$291K Sell
1,718
-1,503
-47% -$257K 0.01% 625
2025
Q4
$539K Sell
3,221
-79
-2% -$12.8K 0.01% 516
2025
Q3
$497K Buy
3,300
+23
+0.7% +$3.14K 0.01% 500
2025
Q2
$426K Hold
3,277
0.01% 447
2025
Q1
$419K Buy
3,277
+1
+0% +$136 0.01% 456
2024
Q4
$433K Sell
3,276
-14
-0.4% -$1.97K 0.01% 422
2024
Q3
$479K Buy
3,290
+360
+12% +$52.1K 0.01% 407
2024
Q2
$402K Sell
2,930
-35
-1% -$4.67K 0.01% 414
2024
Q1
$407K Buy
2,965
+65
+2% +$8.88K 0.01% 408
2023
Q4
$394K Sell
2,900
-1,472
-34% -$180K 0.01% 412
2023
Q3
$535K Sell
4,372
-60
-1% -$7.63K 0.02% 352
2023
Q2
$563K Sell
4,432
-295
-6% -$38.3K 0.02% 340
2023
Q1
$611K Buy
+4,727
New +$619K 0.03% 327
2022
Q3
Sell
-1,758
Closed -$207K 435
2022
Q2
$207K Hold
1,758
0.01% 418
2022
Q1
$229K Sell
1,758
-242
-12% -$31.5K 0.01% 381
2021
Q4
$305K Buy
+2,000
New +$310K 0.02% 360

Other funds holding IBB

NorthCrest Asset Manangement's IBB Position: Q2 2026 in Review

NorthCrest Asset Manangement increased its iShares Biotechnology ETF (IBB) stake by 17% in Q2 2026, buying an estimated $51.6K and bringing the position to 2,018 shares worth $398K. The position accounts for 0.01% of the portfolio, ranked #626.

NorthCrest Asset Manangement first reported a position in IBB in Q4 2021 and has held it in 17 quarters since. The position peaked at $611K in Q1 2023. 601 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • NorthCrest Asset Manangement held 2,018 shares of iShares Biotechnology ETF worth $398K as of Q2 2026.
  • NorthCrest Asset Manangement bought 300 iShares Biotechnology ETF shares in Q2 2026, an estimated $51.6K.
  • iShares Biotechnology ETF made up 0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #626 holding.
  • NorthCrest Asset Manangement first reported a position in iShares Biotechnology ETF in Q4 2021 and has held it in 17 quarters since.
  • NorthCrest Asset Manangement's iShares Biotechnology ETF position peaked at $611K in Q1 2023.
  • 601 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.